Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
S. Piperno-Neumann
Institution:
Institut Curie
Observed institution:
Institut Curie
OpenAlex ID:
A5160705428
2104P Darovasertib with crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma (OptimUM-02): A subgroup analysis
2026
·
S. Piperno-Neumann
, E. Ramelyte
, et al.
·
Annals of Oncology
3488P Profiles of patients with metastatic cancer in progression based on their prognostic information preference
2026
·
A. Brédart
, J-L. Kop
, et al.
·
Annals of Oncology
2093P PLUME: Overall survival results from a phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM)
2026
·
M.J. Rodrigues
, V. Servois
, et al.
·
Annals of Oncology
2152eP Tebentafusp discontinuation after sustained disease control in metastatic uveal melanoma (mUM): A single-center ambispective observational study
2026
·
R. Sanchez
, S. Dureau
, et al.
·
Annals of Oncology
Using liver-directed therapies as backbone for combination-treatments in metastatic uveal melanoma
2026
·
A. Wong
, E. Kapiteijn
, et al.
·
ESMO rare cancers.
PDF
Show more works
View as search
Works count:
5
Citation count:
H-index:
I10-index:
Year
Topic
Type